FRANKLIN LAKES, N.J., Aug. 13, 2013 /PRNewswire/ -- BD Medical, a segment of BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today the launch of BD Sterifill Advance, a new prefillable polymer syringe specially engineered to deliver large volume injectable drugs by way of intravenous infusion.
BD Sterifill Advance is a 50 mL plastic prefillable syringe made with a highly advanced cyclic olefin polymer that is designed to offer a number of advantages to drug manufacturers and healthcare professionals including reduced breakage, glass-like transparency, and low levels of extractables. This unique polymer combined with a specific coating technology provides smooth gliding, ensuring an accurate and consistent infusion rate.
"BD applied our extensive knowledge and experience with prefillable syringes to design this new syringe with properties that support the delivery of large volume injectable drugs, making the advantages of this option more widely available," said Claude Dartiguelongue, President, BD Medical - Pharmaceutical Systems. "We are offering drug developers, healthcare workers and patients a new option for prefill drug delivery that sets new standards in both safety and convenience."
The BD Sterifill Advance Plastic Prefillable Syringe aims to provide a seamless transition for healthcare workers in the hospital setting because the syringe was developed from the design of BD Plastipak, a leading disposable syringe. This unique design avoids any syringe pump reprogramming activity for hospitals and aims to reduce risks of administration errors for healthcare workers. In addition, the syringe has been designed to be highly durable, reducing the probability of flange breakage and ensures a reliable connection with syringe pumps.
The syringe can address a number of drug delivery needs for the intravenous infusion of large volumes of drugs including: anesthesia, pain management, cardiac therapy and nutrition amongst others. The product can also be used in a variety of settings for parenteral administration of pharmaceutical compounds.
BD is a leading global medical technology company that develops, manufactures and sells medical devices, instrument systems and reagents. The Company is dedicated to improving people's health throughout the world. BD is focused on improving drug delivery, enhancing the quality and speed of diagnosing infectious diseases and cancers, and advancing research, discovery and production of new drugs and vaccines. BD's capabilities are instrumental in combating many of the world's most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs nearly 30,000 associates in more than 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. For more information, please visit www.bd.com.
SOURCE BD-Becton Dickinson